Progressive visual disturbance and enlarging prolactinoma caused by melanoma metastasis
A case report and literature review
Chuanwei Yang, MM',a, Ling Liu, MM', Xiaqiang Lan, MM', Shiqiang Zhang, MM', Xinyu Li, MD',c, Bo Zhang, MD'a,b

Abstract
Rationale: Melanoma metastases to the pituitary adenoma (MMPA) are extremely rare, with only 1 reported case. To date, the melanoma metastasis to the existing prolactinoma has not been reported in literature.

Patient concerns: We report a case of 62-year-old woman presented with progressive visual disturbance and hyperprolactinemia. Magnetic resonance imaging demonstrated the presence of a round sellar mass.

Diagnoses: Melanoma metastasis to the pituitary adenoma.

Interventions: Surgery was performed and intraoperative frozen section examination found melanin granules and histopathological examination confirmed melanoma metastasis to the pituitary adenoma.

Outcomes: After surgery, the patient developed widespread melanoma metastasis to lower limbs. Twenty-two months later, the patient was alive with worse symptoms.

Lessons: We reviewed and analyzed the clinical data, imaging features, and treatment methods of other reported cases of metastases to pituitary adenoma (MPA). This study provides clinical information for the diagnosis and management of MMPA.

Abbreviations: CT = computed tomography, MMPA = melanoma metastasis to the pituitary adenoma, MPA = metastasis to pituitary adenoma, MRI = magnetic resonance imaging.

Keywords: diagnosis, melanoma metastasis to the pituitary adenoma, metastases to pituitary adenoma, treatment

1. Introduction
Melanoma has been the fastest-growing malignant tumor in incidence, annual rate of increase of which was 3% to 5%, but the mortality rate did not rise accordingly.[1] Many melanoma patients died of deterioration of multiple system metastases. It is known that metastatic melanoma has a high affinity to the brain. Thirty-nine percent of patients who died of melanoma showed brain metastasis, while the number who showed pituitary metastasis was less than 5%.[2] Involvement of the existing pituitary adenoma is distinctly rare and intractable. To date, the melanoma metastasis to the existing prolactinoma has not been reported in literatures. Therefore, little information is available regarding the clinical and imageology characteristics of melanoma metastasis to the pituitary adenoma (MMPA).

In this study, we present the first reported case of melanoma metastasis to the existing prolactinoma in a 62-year-old woman, who presented with progressive visual disturbance, headache, and hyperprolactinemia. In addition, we reviewed other known cases of metastases to pituitary adenoma (MPA). Our study provides important clinical information for diagnosis and management of MMPA.

2. Case report
In March 2015, a 62-year-old woman was admitted to our hospital. She complained of progressive visual disturbance, which began about 4 years ago and was treated as cataract in local hospital, but no relief was seen. On the contrary, the symptoms aggravated half a year ago, together with headache, left eye pain, tearing and increased secretions, and the computed tomography (CT) scan of the brain in local hospital showed a sellar region lesion. Besides, 2 years earlier, the patient underwent resection of melanoma in the left heel (T2N0M0, ki67 3–5%, Stage II), followed by resection of the recurrent melanoma nearby the primary site 15 months later (T3N3M0, Stage III), without lymphadenectomy. She had no family history of melanoma.
On physical examination, the patient had bilateral temporal hemianopsia, the right finger counting was 1 m, and the left finger counting was no more than 0.5 m. Enlarged lymph nodes were palpable in the right groin. On ophthalmologic examination, the patient had right vision of 0.4 and left vision of 0.08, with the same intraocular pressure 15 mm Hg bilaterally. The optometry found the right eye of +6.00DS/+0.25DC 65° and the left eye of +6.25DS/+0.50DC 20°. The patient had maculopathy of both eyes and optic atrophy of the left eye. Light reflex and eye movement of both eyes were normal. CT scans of the brain parenchyma, orbital, and chest were unremarkable. CT scan and ultrasound examination of the abdomen showed hepatic portal and retroperitoneal lymphadenectasis and enlarged left lobe of the liver with substantial placeholder lesions. Ultrasound examination of bilateral inguinal lymph nodes discovered multiple low echo light groups, the largest of which was 31 mm in diameter, with hilus of the echo and asymmetrical thickening of the skin. CT scan of sellar region revealed a round mass of 30 mm in diameter in the enlarged sellae (Fig. 1A, B). The mass showed isointense in T1-weighted images (T1-WI) and T2-weighted images (T2-WI), with homogeneous enhancement after Gadolinium-DTPA injection, and dural tail sign was seen. Small foci inside the tumor showed hyperintense signals in T1-WI and hypointense signals in T2-WI, without enhancement. It was seen that the mass penetrated meninges, surrounded the left internal carotid artery, and was blurred with the left optic nerve. Pituitary stalk became shorter with a right displacement. Laboratory findings revealed increased levels of prolactin (119.08 µg/L, normal range 5.99–30.04 µg/L) and cortisol (677.10 nmol/L, normal range 118.60–618.00 nmol/L) and decreased levels of free thyroxine (FT4) (6.04 pmol/L, normal range 12.00–22.00 pmol/L) and free triiodothyronine (FT3) (2.09 pmol/L, normal range 3.50–6.50 pmol/L). The patient was diagnosed with a giant prolactinoma.

The patient underwent transnasal transsphenoidal surgery to remove the tumor and relieve the compression of the optic nerve. Intraoperatively, it was seen that the tumor invaded and filled the left interval of the sphenoid sinus, and part of bone in sellar floor and left side parasellar was destroyed and absorbed. A little normal pituitary tissue was seen in the top right of tumor in the sellar turcica. The tumor was reddish black with extremely rich blood supply and had close adhesion to the surrounding structure. The texture in the center of the tumor was soft and much tougher over the rim. Intraoperative frozen-section examination found melanin granules, and it was considered to be malignant melanoma or meningioma. The tumor cells were composed of eosinophilic staining epithelial cells. Most of cell nuclei were round, a few were reniform and hippocrepiform with evident nucleoli, and nuclear fission was seen. The tumor showed no evidence of necrosis (Fig. 2). The tumor was immunopositive focally for melanoma-specific markers such as S-100, HMB45, and Vimentin, and immunopositive for neuroendocrine tumor markers such as CgA and Syn (Fig. 3). The Ki67 index was 3% to
5%; it was higher in metastatic melanoma than in the adenomatous component. Taken the melanoma history and suspected lymph node and hepatic metastasis into consideration, the patient was diagnosed with MMPA. After surgery, significant relief was seen in visual field and headache, and the level of prolactin, cortisol, and FT4 returned to normal with hormone replacement therapy. Because the focal liver lesions and lymphadenectomy did not cause much discomfort, the patient refused any further surgical intervention or other treatment. She was discharged from the hospital immediately and was disease free until 2 months after the third surgery. The patient successively found new melanoma metastatic sites in the skin of lower left leg, knees, the upper left leg, the left groin and the right groin, and the right leg. At the follow-up in late January 2016, the patient could not walk and live by herself and was depressed. At the latest follow-up, in late January, 2017, the patient was alive with worse symptoms, she had sensory deficits of both legs, which could not move, hyperalgesia of hands and mouth, impaired intelligence, but she lived well with the disease by careful nursing of her daughter.

This study was approved by the Second Affiliated Hospital of Dalian Medical University. The patient provided informed consent.

3. Discussion

Melanoma metastasis to the pituitary gland (MMP) is rare, and MMPA is much rarer. It is known that metastasis is one of the properties of malignant melanoma. Metastatic melanoma cells almost can reach any human organ by lymphatic or blood circulation system. The most common organ involved is lung, followed by liver, small intestine, pancreas, adrenal, heart, kidney, thyroid, and brain. Melanoma metastasis to the brain is not uncommon, while pituitary involvement is rare. To our knowledge, there are no more than 20 cases of pituitary metastatic melanoma reported. The mean age of the patients was 46 years. The common presentations of pituitary metastatic melanoma include headache, extraocular cranial nerve palsy, and diabetes insipidus. The majority of the cases suggested metastatic melanoma in the posterior pituitary, while a small part of cases in the anterior pituitary. This involves 3 different metastatic ways. First, melanoma cells metastasize to the posterior pituitary via the inferior hypophyseal artery, which provide direct blood supply to the posterior pituitary, and then invade the anterior pituitary. Second, melanoma cells pass through the unsound blood–brain barrier of the adenohypophysis and trigonum paraplexus, and settle in the pituitary. Third, melanoma cells disseminate through lymphatic microvessels and flourish in the pituitary.

The reason why the pituitary has an affinity for melanoma cells may be that both the pituitary and the melanoma cells produce proopiomelanocortin (POMC), alpha-melanocyte stimulating hormone (α-MSH), and α-MSH receptor, the levels of which in melanoma patients are much higher than healthy people.[7,8] POMC gives rise to α-MSH, and α-MSH regulates the production of melanin. POMC expressed in pituitary adenoma is much higher than the pituitary.[9,10] Accordingly, it is presumed to be that tumors have a propensity to metastasize to pituitary adenoma.

Metastases of circulating tumor cells to remote organs have to overcome many obstacles, including infiltrating the distal tissue, avoiding the immune defense, and adapting to the local environment, and then settle down and flourish and take the place of the host cells. Because of this, efficiency of metastases is not high.[11] To date, there is only 1 case reported regarding melanoma metastasis to pituitary adenoma (Table 1)[12] and 26 cases of different tumors metastatic to pituitary adenoma (Table 2).[13–34] Tumor metastasis to tumor is rare in clinical practice and much more intractable, because it is usually accompanied by multiple metastases. The mean age of the MPA and MMPA patients was 67 and 68.5 years, respectively, much older than MMP. The common aggressive high-grade seed tumors most often metastasize to pituitary adenoma are lung cancer in man, breast cancer in woman, followed by tumor from kidney, stomach, pancreas, colorectum, and pelvis. And the
Table 1
Clinical characteristics of 2 cases of MMPA.

| No. | Author | Sex | Age | Primary tumor | Extra-pituitary tumor | Clinical presentation | Other metastases | Survival time (months) | Treatment |
|-----|--------|-----|-----|---------------|-----------------------|----------------------|------------------|-----------------------|-----------|
| 1   | The present case/2016 | F | 62 | Melanoma in the left heel | Multiple metastases to the pituitary adenoma | Hyperprolactinemia, headache, left eye pain, bilateral temporal hemianopsia | Transphenoidal surgery | 20 | 4 |
| 2   | et al [12] | M | 70 | Subungual acral lentiginous melanoma | Multiple metastases to the pituitary adenoma | Hyperprolactinemia, hypothyroidism, partial insufficiency of ACTH | Transphenoidal surgery | NA | NA |

Common receptor pituitary adenomas are nonfunctional adenoma, prolactinoma, and FSH/LH adenoma (Tables 1 and 2). Pituitary adenomas usually possess direct arterial supply from carotid and capsular vessels, which promote the development of metastasis. As in our case, the tumor surrounded the internal carotid and had rich blood supply. To the best of our knowledge, ours was the first reported case of melanoma metastasis to an already existing enlarged prolactinoma. It was suggested that the prolactinoma began to develop since 4 years ago, when the visual disturbance began to deteriorate. Together with lymph nodes metastases, melanoma cells settled in the prolactinoma via direct blood supply or via blood and lymph circulation in the meninges nearby the sella.

Visual disturbance, headache, cranial nerves palsy were most common seen in metastases to pituitary adenoma (MPA). Most of the pituitary adenomas in the cases were clinically nonfunctioning. Functional pituitary adenomas included prolactinoma, somatotropinoma. Pituitary metastases and MPA usually cause hypopituitarism, as we can conclude that the anterior pituitary and posterior pituitary are usually involved in MPA. In the present case and the case of melanoma metastasis to the pituitary oncocytoma, both patients presented progressive visual disturbance, hyperprolactinemia, and slight hypothyroidism (Table 1). MMPA led to the rapid enlarging sella mass and deterioration of the situation, probably because the melanoma cells and the products could irritate the enlargement of the prolactinoma and deteriorate the optic compression.

Imaginology examinations are helpful in preoperative discovery of MMPA. Intracranial melanoma metastasis is usually present in a single site. CT scan mostly shows round, homogeneous, high-density signal, usually with adjacent bone destruction. Heterogeneous and low-density signal can also be seen. The MRI findings generally change with the content of melanin and intratumoral hemorrhage. First, melanotic metastasis usually presents as hyperintense in T1-weighted images (T1-WI) and hypointense in T2-weighted images (T2-WI). Second, nonmelanotic metastasis usually presents as hypo- or iso-intense in T1-WI and hyper- or iso-intense in T2-WI. Third, the mixed type usually presents as heterogeneous signal. Fourth, the hematoma type usually has complex presentation as the hematoma develop. Notably, as shown in our case, the hyperintense signals of posterior pituitary disappeared in T1-WI and pituitary stalk became thicker with a displacement, probably due to the invasion of the posterior pituitary by melanoma. As in our case, the T1-WI revealed isointense signal and focal hyperintense signal and T2-WI revealed isointense and focal hyperintense signals, and dural tail sign was also seen. Melanin in MRI usually shows hyperintense signal in T1WI and hypointense in T2WI (Table 1). However, in the early disease progression, the melanin in the metastatic sites could be very little and ignored by doctors. The differential diagnosis includes invasive pituitary adenoma, craniopharyngioma, and meningioma. Combination of imaginology findings with clinical findings and disease history can help to diagnose MMPA preoperatively.

Traditional treatment, including surgery, radiotherapy, chemotherapy, has an important role in the management of MPA patients, but they are suggested to be palliative. Total resection of the tumor is often very difficult because of the invasive growth, close adhesion with optic nerves, and rich blood supply. Besides, the metastatic melanoma is not sensitive to radiation therapy and chemotherapy. The prognosis is poor in reality. The median survival time after the diagnosis of MPA was 8.2 months. Patients with sole metastasis limited to the pituitary adenoma had a
### Table 2
Clinical characteristics of 26 cases of MPA.

| No. | Author         | Gender/Age, y | Primary tumor/Pathological stage | Extra-pituitary tumor interval, mo | PA interval, mo | Clinical presentation | Pituitary dysfunction | PA phenotype | Character imaging findings | Other metastasis | Treatment                                                                 | Survival time (month) /Status |
|-----|----------------|---------------|----------------------------------|----------------------------------|-----------------|-----------------------|-----------------------|--------------|--------------------------------|---------------------|----------------------------------------------------------------------------|-------------------------------|
| 1   | Sogani et al ²| 64/M          | Lung cancer                      | 0                                | 0               | deteriorating vision loss bilaterally | No                    | Non-functional PA | MRI demonstrated an intrasellar mass arising from the anterior hypophysis with suprasellar extension. | Occipital lobe                | Transsphenoidal surgery, frostedated stereotactic radiotherapy, chemotherapy | NA                           |
| 2   | Fujimori et al ³| 80/M          | Lung cancer                      | NA                               | NA              | Bilateral visual impairment, oculomotor nerve palsy, headache | NA                    | PA           | CT scan revealed a pituitary tumor extending into the suprasellar region and bilateral cavernous sinus. | NA                  | Transsphenoidal surgery, radiation therapy                               | NA                           |
| 3   | Rotondo et al ⁴| 66/M          | Lung cancer                      | 0                                | 0               | Headache | Hyperprolactinemia   | Protuberance | Hormone-negative PA | CT showed an intra- and suprasellar mass and a left frontal intrasellar lesion suggestive of a metastasis. | Multiple metastases           | Transsphenoidal surgery                                                  | Few days/Dead                  |
| 4   | Hoellig et al ⁵| 71/M          | Lung cancer                      | 6                                | 4 y             | Loss of vision, oculomotor nerve palsy | No                    | Hormone-negative PA | MRI showed a uniformly enhancing lesion in the right parietal lobe and a large left frontal intrasellar lesion suggestive of a metastasis. | Multiple metastases           | Transsphenoidal surgery                                                  | 3 days/Dead                   |
| 5   | Nasr et al ⁶ | 44/F          | Lung cancer                      | 7 y                               | 0               | Bitemporal anosia, acromegaly | High level of GH | Somatotropinoma | MRI demonstrated a mass in the sella turcica, extending into the suprasellar cistern, surrounding the pituitary stalk and compressing the optic chiasm, with mixed low signal in T1WI, increased signal in T2WI, with inhomogeneous enhancement. | Multiple metastases           | Transsphenoidal surgery                                                  | 3/Alive                        |
| 6   | Hurley et al ⁷ | 76/M          | Lung cancer                      | NA                               | 6               | Nausea, lethargy, visual disturbance, acromegaly | High level of GH | Somatotropinoma | NA                  | Multiple metastases           | Transsphenoidal surgery, radiation therapy                               | Dead                          |
| 7   | Post et al ⁸ | 77/M          | Lung cancer                      | Unknown                          | 0               | Headache, loss of vision, bilateral oculomotor nerve palsy, Syndrome of Inappropriate Antidiuretic Hormone | No                    | Orchiocytic PA | NA                  | Multiple metastases           | Transsphenoidal surgery, radiation therapy                               | 6/Dead                        |
| 8   | Malinatzi et al ⁹ | 72/M    | Lung cancer                      | 1 y                               | 0               | Oculomotor nerve palsy, visual loss, bilateral hemianopsia | No                    | Hormone-negative PA | NA                  | Multiple metastases           | Transsphenoidal surgery, radiation therapy                               | 1/Dead                        |
| 9   | Bret et al ¹⁰ | 75/F          | Breast cancer                    | 3 y                               | 0               | Bilateral visual disturbance | No                    | FSHLH PA     | MRI showed a large sellar mass with suprasellar extension, | None                            | Transsphenoidal surgery                                                  | 18/Dead                       |
| 10  | Zager et al ¹¹ | 56/F          | Breast cancer                    | 1 y                               | 0               | Headache, nausea, vomiting, bilateral abducens nerve palsy | No                    | FSHLHGH PA   | CT revealed multiple enhancing bony lesions of the clavus and sphenoethmoid. | Multiple metastases           | Radiation therapy                                                        | 3/Dead                        |
| 11  | van der Zwan et al ¹² | 73/F    | Breast cancer                    | 3 y                               | 0               | Vision loss, hemianopsia in the left eye | No                    | Chromophobe PA | NA                  | Multiple metastases           | Transcranial surgery                                                    | 1/Dead                        |
| 12  | Richardson et al ¹³ | 70/F | Breast cancer                    | 15 y                              | 8               | Headache, left hemiparesis | No                    | Adenocarcinoma | NA                  | Multiple metastases           | Transcranial surgery, radiation therapy                                  | 4/Dead                        |
| 13  | Magroli et al ¹⁴ | 76/F   | Clear Cell Renal Cell Carcinoma | 0                                | 0               | Diplopia, progressive loss of vision, left eyelid ptosis | Hyperprolactinemia | FSHLH subunit | CT scan showed a large intrasellar mass with suprasellar extension. | Multiple metastases           | Transsphenoidal surgery                                                  | 24/Dead                       |
| 14  | Weber et al ¹⁵ | 62/F          | Clear Cell Renal Cell Carcinoma  | 4 y                               | 0               | Headache, visual loss | No                    | Hormone-negative PA | MRI showed a large sellar mass with suprasellar extension. | Multiple metastases           | Transcranial surgery                                                    | 8/Dead                        |
| 15  | James Jr et al ¹⁶ | 75/M | Clear Cell Renal Cell Carcinoma | 9 y                               | 25 y            | Visual disturbance | No                    | Hormone-negative PA | MRI showed a large sellar mass with suprasellar extension. | Multiple metastases           | Transcranial surgery                                                    | NA                           |
| 16  | van Seters AP et al ¹⁷ | 66/F | Stomach cancer                  | 0                                | 17 y            | Headache, visual disturbance, sudden blindness of left eye | Hyperprolactinemia | PRL-secreting PA | MRI showed a large sellar mass with suprasellar extension. | Multiple metastases           | Transcranial surgery                                                    | 12.6/Dead                     |
| 17  | Molinatti et al ¹⁸ | 66/F | Stomach cancer                  | 0                                | 18 y            | Headache, nausea, sudden blindness of left eye | Hyperprolactinemia | PRL-secreting PA | MRI showed a large sellar mass with suprasellar extension. | Multiple metastases           | Transcranial surgery                                                    | 2/Dead                        |

(continued)
| No. | Author               | Gender/Age (y) | Primary tumor/Pathological stage | Extra-pituitary tumor interval (mo) | Clinical presentation | Pituitary dysfunction | PA phenotype | Character imaging findings | Other metastasis                  | Treatment                  | Survival time (month)/Status |
|-----|----------------------|----------------|---------------------------------|-------------------------------------|------------------------|-----------------------|--------------|--------------------------|-----------------------------------|-----------------------------|-----------------------------|
| 18  | Ramsay et al [29]    | 50/F           | Poorly differentiated neuroendocrine carcinoma from pancreas | 6                                   | Exophthalmos, obesity | High level of ACTH     | ACTH Cooke cell PA | NA                      | Multiple metastases               | Radiation therapy, chemotherapy  | 7/Dead                      |
| 19  | Ramsay et al [29]    | 67/M           | Pancreas cancer                 | 9 y                                 | NA                     | No                    | Hormone-negative PA | NA                      | Bone, liver, lymph nodes          | None                        | Dead                        |
| 20  | Thewjitcharoen et al [30] | 65/M         | Advanced colorectal cancer      | 0                                   | Left eye ptosis, visual disturbance, severe headache, nausea, lightheadedness, decrease in libido | Hyperprolactinemia,  | Prolactinoma         | MRI showed a sellar mass with left cavernous sinus invasion, with inhomogeneous signal intensity in T1WI and hypointensity in T2WI, with heterogeneous enhancement. | Liver, lung                     | Transsphenoidal surgery, chemotherapy, radiation therapy | 9/Dead                      |
| 21  | Naga et al [31]      | 60/M           | Rectum cancer                   | 0                                   | Loss of vision, hemianopsia | No                    | Hormone-negative PA | MRI showed a lesion with extension into the sphenoid sinus, and the midline shift increased to 7 mm. | Multiple metastases               | Transcerebral surgery           | Few days/Dead                 |
| 22  | Burns et al [32]     | 75/M           | Kidney cancer                   | 0                                   | Fever, nausea, diarrhea | No                    | Nonfunctional PA    | MRI of the sella showed a mass with left parasellar and suprasellar extensions, enhanced mass in the enlarged sella, and extension into suprasellar cistern. | Multiple metastases               | Transphenoidal surgery, radiation therapy | 5/Dead                      |
| 23  | Nassiri et al [33]   | 55/F           | Neuroendocrine tumor of unknown primary origin | 0                                   | Leg pain, acromegaly | No                    | GH-producing pituitary adenoma | MRI showed a lesion with extension into the sphenoid sinus, with mild left optic compressive neuropathy | Multiple metastases               | Transphenoidal surgery          | 21/Dead                     |
| 24  | Abe et al [34]       | 46/F           | Malignant carcinoid tumor in mediastinum | 1 year                              | Headache, visual disturbance, hemianopsia | Hyperprolactinemia   | Prolactinoma         | MRI showed a homogenous, enhancing mass in the enlarged sella, compression of the optic tract. | Multiple metastases               | Transphenoidal surgery          | NA/Dead                      |
| 25  | Bret et al [35]      | 87/M           | Unknown                         | 0                                   | Bilateral visual disturbance, optic nerve atrophy | No                    | FSH/LH PA            | MRI showed an intrasellar mass with suprasellar and right-sided parasellar extension and compression of the optic tract. | None                            | Transphenoidal surgery          | 6/Alive                      |
| 26  | Post et al [36]      | 61/F           | Unknown                         | 0                                   | Headache, visual disturbance | No                    | Nonfunctional ACTH   | NA                      | None                            | Transphenoidal surgery          | Alive                       |

Extra-pituitary tumor interval (month), the time from the diagnosis of extra-pituitary tumor to the diagnosis of pituitary adenoma. PA interval (month), the time from the diagnosis of pituitary adenoma to the diagnosis of metastases to the pituitary adenoma.
ACTH = adrenocorticotropic hormone, CT = computed tomography, F = female, FSH = follicle stimulating hormone, GH = growth hormone, LH = luteinizing hormone, M = male, MRI = magnetic resonance imaging, NA = not available, PA = pituitary adenoma, PRL = prolactin, T1WI = T1-weighted image, T2WI = T2-weighted image.
median survival of 12 months versus 7.7 months of patients with multiple metastases (Tables 1 and 2). As shown in our case, the survival time after surgery is more than 22 months; we believe that early diagnosis and total resection as much as possible may slow down the disease progression and have an influence on survival. Nowadays, some new adjuvant therapies and drugs have been introduced to treat advanced melanoma. For example, high-dose interferon therapy, ipilimumab in targeted immunotherapy, BRAFV600E inhibitor vemurafenib, KIT inhibitor imatinib, and T-EC and PV-10 can induce local tumor ablation and tumor cell immune.\cite{1,19} It is suggested that patients with metastatic melanoma who received adjuvant therapies had better survival than those who did not. Notably, emotional support, social support, and stress management have a positive effect on patients’ body and mind and help provide better survival.\cite{40} As metastasis is the key of the intractable situation, it is advisable that cell track which can capture and isolate circulating tumor cells from peripheral blood will play a great role in future in routine monitoring of cancer development and therapy,\cite{1,19} including the management of MMP, MPA, and MMPA.

In conclusion, we present a rare case of MMPA. Together with the increasing number of patients with melanoma and longer survival time, the number of patients with melanoma metastases and MMPA is likely to increase. The presence of MMPA usually mimics pituitary adenoma, but MMPA should be taken into consideration in patients over 60 years old, with a history of pituitary adenoma and melanoma, especially the multiple metastatic melanoma, and had rapidly aggravated visual disturbance, and characteristic manifestation of melanin in MRI. Combination of imaginology findings with clinical findings and disease history is of great importance for preoperative diagnosis of MMPA. Traditional treatments followed by adjuvant therapies including high-dose interferon therapy, targeted immunotherapy, mutated gene inhibitors may be helpful for improving the survival of patients with MMPA.

References

[1] Guo J, Qin S, Liang J, et al. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Ann Transl Med 2015; 3:322.

[2] Dasgupta T, Brasfield R. Metastatic melanoma: a clinicopathological study. Cancer 1964;17:1323–39.

[3] McCutcheon IE, Waguespack SG, Fuller GN, et al. Metastatic melanoma to the pituitary gland. Can J Neurol Sci 2007;34:322–7.

[4] Leung GK, Chow WS, Tan KC, et al. Metastatic melanoma of the pituitary gland. Case report. J Neurol Neurosurg Psychiatry 2003;69:913–5.

[5] Yang C, Zhang H, Zhang S, et al. Oculomotor paralysis, postorbital pain, and hypopituitarism as first presentations of metastatic gastric cancer in the pituitary gland. J Neurol Neurosurg Psychiatry 2004;74:369–77.

[6] Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337–41.

[7] Funasaka Y, Sato H, Chakraborty AK, et al. Expression of proopio-melanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, neuroc cells, and normal human melanocytes. J Invest Dermatol Symp Proc 1999;4:105–9.

[8] Williams RR. Breast and thyroid cancer and malignant melanoma promoted by alcohol-induced pituitary secretion of prolactin, T.S.H and M.S.H. Lancet 1976;1:996–9.

[9] Chan JS, Gaspar L, Iguchi H, et al. Synergistic effects of ovine corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on the release of pro-opiomelanocortin (POMC) related peptides by pituitary adenoma of a patient with Nelson’s syndrome in vitro. Clin Invest Med 1984;7:205–8.

[10] Cassarino MF, Sesta A, Pagliardini L, et al. AZA-deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. Pituitary 2014;17:464–9.

[11] Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature 2016;529:298–306.

[12] Jang SM, Hsu YY, Chuang CC, et al. A man in his mid-70 s with a sellar mass, Brain Pathol 2007;17:115–6,121.

[13] Sogani J, Yang W, Lavi E, et al. Sellar collision tumor involving metastatic lung cancer and pituitary adenoma: radiologic-pathologic correlation and review of the literature. Clin Imaging 2014;38:318–21.

[14] Fujimori T, Okauchi M, Shindo A, et al. Intrapituitary adenoma metastasis from lung cancer with progressive cranial nerve palsies: a case report and literature review. No Shinkei Geka 2014;42:943–9.

[15] Rotondo F, Kovacs K, Macdonald RL, et al. Non-small cell bronchial carcinoma metastasizing into a prolactin producing pituitary adenoma. Int J Surg Pathol 2013;21:68–71.

[16] Hoefl A, Niehusmann P, Flacke S, et al. Metastasis to pituitary adenoma: case-report and review of the literature. Cent Eur Neurosurg 2009;70:149–53.

[17] Nair C, Mason A, Mayberg M, et al. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab 2006;91:4776–80.

[18] Hurley TR, D’Angelo CM, Glassen RA, et al. Adenocarcinoma metastatic to a growth-hormone-secreting pituitary adenoma: case report. Surg Neurol 1992;37:361–5.

[19] KD, McCormick PC, Hays AP, et al. Metastatic carcinoma to pituitary adenoma. Report of two cases. Surg Neurol 1988;30:286–92.

[20] Molinatti PA, Scheithauer BW, Randall RV, et al. Metastasis to pituitary adenoma. Arch Pathol Lab Med 1985;109:287–9.

[21] Breet P, Jouvet A, Madarassy G, et al. Visceral cancer metastasis to pituitary adenoma: report of two cases. Surg Neurol 2001;55:284–90.

[22] Zager EL, Hedley-Whyte ET. Metastasis within a pituitary adenoma presenting with bilateral abducens palsies: case report and review of the literature. Neurosurgery 1987;21:383–5.

[23] van der Zwan A, Luyendijk W, Bots GT. Metastasis of mammary carcinoma in a chromophobe adenoma of the hypophysis. Psychiatr Neurol Neurochir 1971;74:369–77.

[24] Richardson JF, Katayama L. Neoplasm to neoplasm metastasis. An acidophil adenoma harbouring metastatic carcinoma: a case report. Arch Pathol 1971;91:135–9.

[25] Magnoli F, Finzi G, Riva C, et al. Renal cell carcinoma metastatic to a pituitary gland. Can J Neurol Sci 2007;34:322–7.

[26] Weber J, Gassel AM, Hoch A, et al. Concomitant renal cell carcinoma with pituitary adenoma. Acta Neurochir (Wien) 2003;145:227–31.

[27] James RL Jr, Arsenis G, Stoler M, et al. Hypophyseal metastatic renal cell carcinoma presenting with pituitary adenoma. Ultrastruct Pathol 1985;16:813–7.

[28] Weber J, Gasel AM, Hoch A, et al. Concomitant renal cell carcinoma with pituitary adenoma. Ultrastruct Pathol 1976;9:132–5.

[29] D’Angelo CM, Liston RA, et al. Adenocarcinoma metastatic to a pituitary adenoma: report of two cases. Exp Clin Endocrinol 1992;90:69–76.

[30] Thewitcharoen Y, Shuangshoti S, Lerdlum S, et al. Colorectal cancer manifesting with metastasis to pituitary adenoma: report of a case involving symptoms mimicking pituitary apoplexy, Intern Med 2004;43:1963–9.

[31] Noga C, Prayson RA, Kowalski R, et al. Metastatic adenocarcinoma to a pituitary adenoma. Ann Diagn Pathol 2001;5:354–60.

[32] Bums WA, Kadar AT. Unusual metastases from a transitional-cell carcinoma of the renal pelvis and ureter. Med Ann Dist Columbia 1973;42:65–6.

[33] Nasr C, Mason A, Mayberg M, et al. Oculomotor paralysis, postorbital pain, and hypopituitarism as first presentations of metastatic gastric carcinoma metastasizing into a prolactinoma during bromocriptine therapy: a case report with a review of the literature. Neuropsychiatr Dis Treat 2014;10:430–7.

[34] James RL Jr, Arsenis G, Stoler M, et al. Hypophyseal metastatic renal cell carcinoma presenting with pituitary adenoma. Acta Neurochir (Wien) 2003;145:227–31.

[35] Burns WA, Kadar AT. Unusual metastases from a transitional-cell carcinoma of the renal pelvis and ureter. Med Ann Dist Columbia 1973;42:65–6.

[36] Noga C, Prayson RA, Kowalski R, et al. Metastatic adenocarcinoma to a pituitary adenoma. Ann Diagn Pathol 2001;5:354–60.

[37] Burns WA, Kadar AT. Unusual metastases from a transitional-cell carcinoma of the renal pelvis and ureter. Med Ann Dist Columbia 1973;42:65–6.

[38] Nasr C, Mason A, Mayberg M, et al. Oculomotor paralysis, postorbital pain, and hypopituitarism as first presentations of metastatic gastric cancer in the pituitary gland. J Neurol Neurosurg Psychiatry 2003;74:135–9.

[39] Noga C, Prayson RA, Kowalski R, et al. Metastatic adenocarcinoma to a pituitary adenoma. Ann Diagn Pathol 2001;5:354–60.
[36] Yamamoto J, Kakeda S, Shimajiri S, et al. Tumor consistency of pituitary macroadenomas: predictive analysis on the basis of imaging features with contrast-enhanced 3D FIESTA at 3T. AJNR Am J Neuroradiol 2014;35:297–303.

[37] Atlas SW, Grossman RI, Gomori JM, et al. MR imaging of intracranial metastatic melanoma. J Comput Assist Tomogr 1987;11:577–82.

[38] Gerber NK, Young RJ, Barker CA, et al. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 2015;121:159–65.

[39] Mackiewicz-Wysocka M, Krokowicz L, Kocur J, et al. Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient. Medicine (Baltimore) 2014;93:e137.

[40] Spiegel D. Mind matters in cancer survival. JAMA 2011;305:502–3.

[41] Fan X, Jia C, Yang J, et al. A microfluidic chip integrated with a high-density PDMS-based microfiltration membrane for rapid isolation and detection of circulating tumor cells. Biosens Bioelectron 2015;71:380–6.